0.7301
전일 마감가:
$0.738
열려 있는:
$0.73
하루 거래량:
59,679
Relative Volume:
0.39
시가총액:
$28.49M
수익:
$135.87M
순이익/손실:
$72.20M
주가수익비율:
0.5142
EPS:
1.42
순현금흐름:
$45.09M
1주 성능:
+0.70%
1개월 성능:
-2.52%
6개월 성능:
-31.77%
1년 성능:
-64.98%
Scynexis Inc Stock (SCYX) Company Profile
명칭
Scynexis Inc
전화
201-884-5485
주소
1 EVERTRUST PLAZA, JERSEY CITY, NJ
SCYX을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
SCYX
Scynexis Inc
|
0.7301 | 28.80M | 135.87M | 72.20M | 45.09M | 1.42 |
![]()
ZTS
Zoetis Inc
|
152.12 | 68.04B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.48 | 46.30B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
HLN
Haleon Plc Adr
|
9.88 | 44.25B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.54 | 18.73B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
304.50 | 13.82B | 2.99B | 1.21B | 1.13B | 25.06 |
Scynexis Inc Stock (SCYX) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2021-01-22 | 개시 | Guggenheim | Buy |
2021-01-06 | 개시 | Cantor Fitzgerald | Overweight |
2018-07-11 | 업그레이드 | Needham | Hold → Buy |
2018-06-27 | 개시 | Maxim Group | Buy |
2017-10-24 | 개시 | Guggenheim | Buy |
2017-07-10 | 개시 | ROTH Capital | Buy |
2017-05-09 | 다운그레이드 | Needham | Buy → Hold |
2017-03-03 | 재확인 | RBC Capital Mkts | Outperform |
2016-10-20 | 개시 | H.C. Wainwright | Buy |
2016-10-07 | 업그레이드 | WBB Securities | Buy → Strong Buy |
2016-10-03 | 재개 | Brean Capital | Buy |
2016-08-17 | 개시 | Guggenheim | Buy |
2016-08-09 | 재확인 | Needham | Buy |
2016-08-09 | 업그레이드 | WBB Securities | Speculative Buy → Buy |
2016-03-28 | 개시 | Brean Capital | Buy |
2015-12-29 | 개시 | WBB Securities | Speculative Buy |
2015-11-16 | 재확인 | RBC Capital Mkts | Outperform |
2015-06-10 | 개시 | Needham | Buy |
2014-05-29 | 개시 | Canaccord Genuity | Buy |
2014-05-29 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Scynexis Inc 주식(SCYX)의 최신 뉴스
Is SCYNEXIS Inc. a good long term investmentTremendous growth opportunities - Autocar Professional
What drives SCYNEXIS Inc. stock priceFastest return on investment - Autocar Professional
What analysts say about SCYNEXIS Inc. stockUnstoppable profit momentum - Autocar Professional
SCYNEXIS Inc. Stock Analysis and ForecastFast-track wealth growth - Autocar Professional
Is ATH.PRA a good long term investmentSkyrocketing returns - Jammu Links News
What makes SCYNEXIS Inc. stock price move sharplyTop Analyst Picks - Newser
Why SCYNEXIS Inc. stock attracts strong analyst attentionGrowth Stock Monitor - Newser
How SCYNEXIS Inc. stock performs during market volatilityFree Stock Market Analysis Courses - Newser
Scynexis Inc (SCYX) Stock: A Year of Highs and Lows in the Market - investchronicle.com
SCYNEXIS Holds Annual Meeting, Re-elects Directors - The Globe and Mail
SCYNEXIS Faces Nasdaq Delisting Notice for Stock Price - TipRanks
Millennium Management LLC Takes Position in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World
Squarepoint Ops LLC Takes Position in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World
Jane Street Group LLC Buys New Holdings in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) & SCYNEXIS (NASDAQ:SCYX) Head-To-Head Survey - Defense World
Biosergen taps antifungal expert as board member - Biostock
Northern Trust Corp Has $186,000 Stake in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World
Scynexis resumes dosing in Phase III MARIO study after lengthy delay - MSN
SCYNEXIS resumes Phase 3 antifungal study after FDA lift By Investing.com - Investing.com South Africa
SCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA Hold - Insider Monkey
Scynexis resumes patient dosing in Phase 3 MARIO study - TipRanks
SCYNEXIS Resumes Patient Dosing In Phase 3 MARIO Study - marketscreener.com
SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study | SCYX St - GuruFocus
GSK Involved in SCYNEXIS's Phase 3 Study Milestone Dispute | GSK Stock News - GuruFocus
SCYNEXIS resumes Phase 3 antifungal study after FDA lift - Investing.com Australia
SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study | SCYX Stock News - GuruFocus
SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study - The Manila Times
Scynexis Inc (SCYX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):